Table 1 Telomere status and clinical variables in non-small cell lung cancers

Gender

142

 Female

12

5.49 ± 0.69

0.274; Mann-Whitney U Test

0.83 ± 0.07

0.416; Mann-Whitney U Test

 Male

130

6.66 ± 0.28

0.94 ± 0.03

TNM stage

142

 I

86

6.08 ± 0.29

0.204; one-way ANOVA

0.91 ± 0.03

0.442; Kruskal-Wallis test

 II

9

7.01 ± 1.37

0.96 ± 0.11

 IIIA

38

7.45 ± 0.57

1.00 ± 0.06

 IIIB

5

6.15 ± 1.55

0.85 ± 0.18

 IV

4

7.79 ± 2.84

0.80 ± 0.10

Size of the primary tumour, T

142

 T1

22

5.54 ± 0.52

0.006; Kruskal-Wallis test

0.93 ± 0.04

0.024; Kruskal-Wallis test

 T2

91

6.32 ± 0.30

0.90 ± 0.03

 T3

22

8.84 ± 0.84

1.11 ± 0.09

 T4

7

5.75 ± 1.10

0.79 ± 0.13

Lymph node dissemination, N

142

 N0

102

6.44 ± 0.30

0.532; Kruskal-Wallis test

0.93 ± 0.03

0.456; Kruskal-Wallis test

 N1

11

7.74 ± 1.22

1.02 ± 0.10

 N2

28

6.64 ± 0.62

0.93 ± 0.07

 N3

1

3.25

0.62

Tumour metastasis, M

142

 Absence, M0

138

6.52 ± 0.26

0.848; Mann-Whitney U Test

0.94 ± 0.03

0.349; Mann-Whitney U Test

 Presence, M1

4

7.79 ± 2.84

0.80 ± 0.10

Histology

141^a

 Squamous cell carcinoma (SCC)

79

6.47 ± 0.33

0.128; Kruskal-Wallis test

0.94 ± 0.03

0.022; Kruskal-Wallis test

 Adenocarcinoma (AD)

56

6.93 ± 0.46

0.96 ± 0.04

 Large cell undifferentiated carcinoma (LCUC)

6

4.31 ± 0.89

0.64 ± 0.10